PatientSpotlight, by PanaceaIntelPatientSpotlight

Topic · Respiratory

Biologics

Coverage of biologics across PatientSpotlight - the developments worth watching, the access reality, and what the next twelve months may bring. 2 pieces on biologics in Respiratory, newest first within each collection.

← All topics
FilterAll (3)Immunology (1)Respiratory (2)

Signals

1
SignalApr 26, 2026FDA · peer-reviewed · conference

Severe asthma biologics: which patients are still being left out?

Type-2 biologics have transformed severe eosinophilic asthma management, but a meaningful subset of severe-asthma patients - those without high eosinophils, FeNO, or specific allergic phenotypes - still lack a biomarker-aligned biologic option.

TreatmentBiologicsPipelineAccess

Explained

1
ExplainedApr 26, 2026peer-reviewed · FDA · guideline-bodies

COPD's biomarker problem and how the field is solving it

COPD has, until recently, been managed as a single condition with a stepwise pharmacological ladder. The arrival of biologics in COPD - and the subgroup-driven trial designs that supported their approval - has forced the field to confront a biomarker question that asthma resolved a decade ago: which patient, which mechanism, which therapy, and how do we know.

CopdBiomarkersBiologicsEosinophils